The Beijing angle closure progression study (BAPS) aims to explore the 5-year incidence of PACS progressing to PAC or PACG and to determine the possible risk factors of disease progression, which may provide the evidence for choosing the accurate strategies in the management of PACS.
Eligibility
Sex
ALL
Min age
40 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
* "Static" gonioscopy identifying 6 or more clock hours of angle circumference in which the posterior (usually pigmented) trabecular meshwork cannot be seen in both eyes with no peripheral anterior synechiae, and normal intraocular pressure (IOP), optic nerve and visual field.
* Able to provide informed consent
Exclusion Criteria:
* Any evidence of primary angle closure (a narrow angle as defined above, but with PAS and/or IOP \> 21 mmHg) or primary angle closure glaucoma (visual field defect or glaucomatous optic neuropathy).
* Previous intraocular surgery or laser treatment, such as cataract surgery, laser trabeculoplasty, trabeculectomy, laser peripheral iridectomy, and laser iridoplasty
* Sign of prior acute attack, such as glaucomatous fleck, keratic precipitates, or iris atrophy.
* Anterior segment structural abnormalities shown by examination, such as iris or ciliary body tumor.
* Severe health problems precluding follow-up such as end-stage heart disease, kidney disease, or lung disease, or terminal cancer.
* Severe eye diseases, such as cataract, macular disease, and retinal detachment.
Primary outcome measure(s)
the progression rate 1 — 6 months the rate of acute angle closureanterior synechiae
the progression rate 2 — 6 months the proportion of eyes developing peripheral
Trial sites (1)
Facility
City
Region
Status
Peking University People's Hospital
Beijing
Beeijing
Recruiting
More Peking University People's Hospital trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.